Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging

Molecular Imaging and Biology

Volumn 14, Issue 1, 2012, Pages 25-31

  Dunphy, Mark P S ^a   Zanzonico, Pat ^a   Veach, Darren ^a   Somwar, Romel ^a   Pillarsetty, Nagavarakishore ^a   Lewis, Jason ^a   Larson, Steven ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Dasatinib (substance name); Molecular imaging; Positron emission tomography; Protein tyrosine kinases Mesh ; SKI 249380

Indexed keywords

FLUORINE 18; ISOFLURANE; RADIOPHARMACEUTICAL AGENT; SKI 249380; UNCLASSIFIED DRUG; DASATINIB; DIAGNOSTIC AGENT; FLUORINE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG EXCRETION; DRUG TISSUE LEVEL; FEMALE; IMAGE ANALYSIS; IMAGING SYSTEM; ISOTOPE LABELING; LARGE INTESTINE; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; URINARY EXCRETION; ANIMAL; ANIMAL MODEL; CHEMISTRY; METHODOLOGY; MOUSE MUTANT; NUDE MOUSE; TISSUE DISTRIBUTION;

ANIMALIA; MUS;

ANIMALS; FEMALE; FLUORINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; MICE, SCID; MODELS, ANIMAL; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; RADIATION DOSAGE; RADIOPHARMACEUTICALS; THIAZOLES; TISSUE DISTRIBUTION;

EID: 84861483884     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0462-2     Document Type: Article

References (17)

1. Luo FR, Barrett Y, Ji P et al (2006) Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003). J Clin Oncol 24(suppl):3046
2. U.S. National Institutes of Health (2010). Available at: http://clinicaltrials.gov/. Accessed 11 June 2010.
3. Demetri GD, Lo Russo P, MacPherson IRJ et al (2009) Phase I doseescalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15:6232-6240
4. Wang L, Christopher LJ, Cui D et al (2008) Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 36:1828-1839
5. Veach DR, Namavari M, Pillarsetty N et al (2007) Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 50:5853-5857 (Pubitemid 350106039)
6. U.S. Food and Drug Administration (2006). Guidance for industry, investigators, and reviewers: exploratory IND studies.
7. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023-1027 (Pubitemid 43733519)
8. Bolch WE, Eckerman KF, Sgouros G, Thomas SR (2009) MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of Nomenclature. J Nucl Med 50:477-484
9. Cristy M, Eckerman K (1987). Specific absorbed fractions of energy at various ages from internal photons sources. VII. Adult Male. ORNL/TM-8381. Oak Ridge National Laboratory, Oak Ridge, TN
10. U.S. Food and Drug Administration (2009). 21 CFR Part 361. Prescription drugs for human use generally recognized as safe and effective and not misbranded: drugs used in research
11. Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, Huang F (2007) Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 8:R255
12. Peck CC, Cross JT (2007) Getting the dose right: facts, a blueprint, and encouragements. Clin Pharmacol Ther 82:12-14
13. Workman P, Aboagye EO, Chung YL et al (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesistesting clinical trials of innovative therapies. J Natl Cancer Inst 98:580-598 (Pubitemid 43904842)
14. Hiwase DK, Saunders V, Hewett D et al (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14:3881-3888
15. Luo FR, Yang Z, Camuso A et al (2006) Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 12:7180-7186 (Pubitemid 44974520)
16. Johnson FM, Agrawal S, Burris H et al (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116:1582-1591
17. National Cancer Institute U.S. National Institutes of Health (2002). A workshop regarding what in-vivo molecular imaging probes are needed to support future translational studies in cancer therapeutics. Paper presented at: Strategies for Imaging Priority Targets, Frankfurt, Germany